Cyclacel Pharmaceuticals (CYCC) succeeds in lung cancer study

Cyclacel Pharmaceuticals announced positive pre-clinical data for its cancer drug candidate, CYC065. The data was presented by independent investigators at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

The data demonstrates that the drug was successful in substantially restraining the growth of cancer, triggering normal and controlled death of cells (called apoptosis), and inducing anaphase catastrophe, a mechanism that specifically targets tumor cells with certain features, in rodents and human lung cancer cells which have high metastatic potential. A metastatic cancer is one can spread from the primary site of origin (where it started) into different area(s) of the body.

The drug also markedly restrained migration and invasion of lung cancer cells and affected distinctive pathways involved in DNA damage response, apoptosis, cell cycle regulation and cell migration.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Key stats and ratios

	Q4 (Dec '16)	2016
Net profit margin	-1024.91%	-1398.69%
Operating margin	-1144.04%	-1678.53%
EBITD margin	-	-1662.75%
Return on average assets	-53.82%	-53.08%
Return on average equity	-74.25%	-72.44%
Employees	13

Address

200 Connell Dr Ste 1500
BERKELEY HEIGHTS, NJ 07922-2811
United States 

Website : 

http://www.cyclacel.com/